Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
Sept 23 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES PHASE 3 EXCALIBER-RRMM STUDY EVALUATING IBERDOMIDE IN COMBINATION WITH STANDARD THERAPIES DEMONSTRATED A SIGNIFICANT IMPROVEMENT IN MINIMAL RESIDUAL DISEASE NEGATIVITY RATES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE OF IBERDOMIDE COMBINATION CONSISTENT WITH PREVIOUS STUDIES
BRISTOL-MYERS SQUIBB CO - IBERDOMIDE WITH STANDARD THERAPIES IMPROVES MRD NEGATIVITY RATES
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Trump Administration Brokers. Intel and Apple Reach Chipmaking Agreement, Shares Surge More Than 13%

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Navitas Stock’s AI Data Center Pivot: Up 88% YTD—Is NVTS Stock Still a Buy?

Tradingkey







